Steven Bernstein, M.D., a leader in lymphoma research, was named to the National Medical and Scientific Advisory Board for the Leukemia & Lymphoma Society, the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services.
His laboratory and clinical research interest centers on immunological approaches to the treatment of lymphoma as well as in the development of novel redox active anti-lymphoma therapeutics. Bernstein is funded by the National Cancer Institute, the Leukemia & Lymphoma Society, and the Lymphoma Research Foundation.
Bernstein also plays a key role in the Wilmot Cancer Center’s major lymphoma research effort. The center holds an $11.5 million grant from the National Cancer Institute to identify and study new therapies for lymphomas. The Specialized Program of Research Excellence grant positions the program among the top four in the nation.
According to the American Cancer Society, about 67,000 adults and children will be diagnosed with lymphoma this year in the United States. Lymphoma incidence rates are rising, which is puzzling to cancer experts because nationally, the number of cancer diagnoses is declining. The Wilmot Cancer Center has approximately 400 doctors, nurses, scientists and support staff dedicated to finding cures for cancer through excellent patient care, novel research and education.